Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising

The complaint centers on advertisements where Eli Lilly allegedly cherry-picked clinical outcomes, comparing its high-dose formulations to lower-dose versions of Novo’s market leaders. By omitting the most recent clinical evidence, the suit claims Lilly has created a distorted picture for consumers, causing tangible harm to the brand’s market standing. Novo pursued informal resolution through a cease-and-desist demand, but the company asserts that Lilly’s subsequent minor revisions failed to address the core inaccuracies.

This litigation highlights the high-stakes nature of the obesity treatment sector, a market projected to surpass $100 billion by 2030. Beyond the balance sheets, the dispute exposes deep friction regarding the regulatory boundaries of direct-to-consumer pharmaceutical advertising in the United States. As both companies fight for dominance, the legal outcome could reshape how manufacturers frame their comparative clinical data in future campaigns.